Search research articles
Contact Us
Filters
Showing results (31-40 of 60) with videos related to
Page
of 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2013
Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089)
Fabrice Barlesi, Arnaud Scherpereel, Achim Rittmeyer, et al.
Lancet (London, England)
|
March 14, 2016
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher, Alexander Spira, Marcus Ballinger, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
May 13, 2022
Symptom relief, prognostic factors, and outcome in patients receiving urgent radiation therapy for superior vena cava syndrome : A single-center retrospective analysis of 21 years' practice
Manuel Guhlich, Teresa Esther Maag, Leif Hendrik Dröge, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 16, 2019
Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study
Shirish M Gadgeel, Rimas V Lukas, Jerome Goldschmidt, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 30, 2024
Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy
Maximilian Hochmair, Michael Schenker, Manuel Cobo Dols, et al.
Cancers
|
June 19, 2024
Therapeutic Patterns and Clinical Outcomes in Limited Disease Small Cell Lung Cancer: A Decade of Analysis at a Tertiary Cancer Center
David Alexander Ziegler, Cecilia Christiane Cleve, Sonia Ziegler, et al.
JTO Clinical and Research Reports
|
January 26, 2026
Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial
Niels Reinmuth, Sébastien Couraud, Luis Paz-Ares, et al.
The Lancet. Oncology
|
May 25, 2019
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West, Michael McCleod, Maen Hussein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 13, 2018
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers
Solange Peters, Rolf Stahel, Lukas Bubendorf, et al.
Clinical & Experimental Metastasis
|
September 26, 2025
The abscopal effect in metastatic lung cancer: a retrospective analysis of combined radiotherapy and immunotherapy
David Alexander Ziegler, Markus Ambold, Markus Anton Schirmer, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 60) with videos related to
Sort By:
Page
of 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2013
Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089)
Fabrice Barlesi, Arnaud Scherpereel, Achim Rittmeyer, et al.
Lancet (London, England)
|
March 14, 2016
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher, Alexander Spira, Marcus Ballinger, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
May 13, 2022
Symptom relief, prognostic factors, and outcome in patients receiving urgent radiation therapy for superior vena cava syndrome : A single-center retrospective analysis of 21 years' practice
Manuel Guhlich, Teresa Esther Maag, Leif Hendrik Dröge, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 16, 2019
Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study
Shirish M Gadgeel, Rimas V Lukas, Jerome Goldschmidt, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 30, 2024
Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy
Maximilian Hochmair, Michael Schenker, Manuel Cobo Dols, et al.
Cancers
|
June 19, 2024
Therapeutic Patterns and Clinical Outcomes in Limited Disease Small Cell Lung Cancer: A Decade of Analysis at a Tertiary Cancer Center
David Alexander Ziegler, Cecilia Christiane Cleve, Sonia Ziegler, et al.
JTO Clinical and Research Reports
|
January 26, 2026
Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial
Niels Reinmuth, Sébastien Couraud, Luis Paz-Ares, et al.
The Lancet. Oncology
|
May 25, 2019
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West, Michael McCleod, Maen Hussein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 13, 2018
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers
Solange Peters, Rolf Stahel, Lukas Bubendorf, et al.
Clinical & Experimental Metastasis
|
September 26, 2025
The abscopal effect in metastatic lung cancer: a retrospective analysis of combined radiotherapy and immunotherapy
David Alexander Ziegler, Markus Ambold, Markus Anton Schirmer, et al.
Page
of 6